Procaps Group S.A. (PROCF)

OTCMKTS · Delayed Price · Currency is USD
1.100
0.00 (0.00%)
Jul 31, 2025, 4:00 PM EDT
Market Cap2.53B
Revenue (ttm)414.10M
Net Income (ttm)52.20M
Shares Out2.30B
EPS (ttm)0.52
PE Ratio2.13
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Average Volume1,866
Open1.100
Previous Close1.100
Day's Range1.100 - 1.100
52-Week Range0.010 - 3.775
Beta53.32
RSI50.44
Earnings DateAug 29, 2025

About Procaps Group

Procaps Group S.A. develops, produces, and markets pharmaceutical solutions worldwide. The company formulates, manufactures, and markets branded prescription drugs in various therapeutic areas, including feminine care products, pain relief, skin care, digestive health, growth and development, cardiology, vision care, central nervous system, and respiratory. It also provides drugs for hospital use, such as antibiotic, blood clot, personal protective equipment, immunosuppressant, oncology, and analgesics products. In addition, the company offers ... [Read more]

Industry Pharmaceutical Preparations
Founded 1977
Employees 5,500
Stock Exchange OTCMKTS
Ticker Symbol PROCF
Full Company Profile

Financial Performance

Financial Statements

News

Procaps Group Secures $130 Million in Equity Investment and Completes Comprehensive Debt Restructuring, as New Investors Take Over Strategic Leadership

New Investors Take Over the Strategic Leadership as Headquarters Move to Bogotá, Marking the Start of a New Chapter of Growth, Execution, and Transformation under Enhanced Governance

4 months ago - GlobeNewsWire

Nasdaq delists Colombia's Procaps Group due to financial shortfalls

Nasdaq recently announced the removal of the Procaps Group due to its failure to complete financial reporting standards on time, a significant decision that illustrates the difficulty that businesses ...

6 months ago - Invezz